Low Incidence of Skin Cancer After Liver Transplant in Non-White Patients
Because of immunosuppressive therapy following liver transplantation, de novo malignancies can occur, and the most common are skin cancers.
Latest News
Latest News
Impact of Salpingo-Oophorectomy on Breast Cancer Risk in Women with BRCA1 and BRCA2 Pathogenic Variants
A team of investigators sought to assess the impact of risk-reducing salpingo-oophorectomy on breast cancer risk in women with BRCA1 and BRCA2 pathogenic variants.
Hypomagnesemia at Time of Transplant Associated With Worse Survival in Patients With DLBCL
Researchers sought to determine whether hypomagnesemia increases the risk of failure for autologous hematopoietic stem cell transplantation in patients with DLBCL.
Certain Mutations May Be Associated With Infection Risk for Patients With Chronic Lymphocytic Leukemia
Researchers sought to determine factors that may impact infection risk in patients with CLL.
Study Finds Tislelizumab Plus Chemotherapy Prolongs PFS in Squamous NSCLC
Investigators report findings from the RATIONALE307 trial that assessed treatment with tislelizumab in patients with squamous NSCLC.
Pembrolizumab Plus Lenvatinib Prolongs Survival in Renal Cell Carcinoma
Investigators report findings from the phase 3 CLEAR trial that assessed outcomes with pembrolizumab plus lenvatinib, lenvatinib plus everolimus, or sunitinib in treatment-naive patients with advanced renal cell carcinoma.
Study Reports Improved Outcomes With Olaparib Maintenance in Ovarian Cancer
A team of investigators conducted a double-blind, placebo-controlled, phase 3 trial to assess outcomes following olaparib treatment in patients with BRCA 1/2-mutated, relapsed ovarian cancer.
Benefit Seen With Ribociclib in Most Breast Cancer Subtypes
A team of investigators conducted a retrospective study to determine the relationship of intrinsic breast cancer subtypes on survival in patients undergoing endocrine therapy plus ribociclib.
MATRix-RICE and Autologous HSCT Beneficial in DLBCL With CNS Involvement
Investigators report on findings from the MARIETTA study, which evaluated an intensive, CNS-directed chemoimmunotherapy followed by autoHSCT in patients with secondary CNS lymphoma.
Opdivo Plus Chemotherapy Approved for First-Line Treatment of Gastric Cancer
The FDA has approved Opdivo (nivolumab) plus chemotherapy for the first-line treatment of patients with gastric cancer.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
